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Abstract
Chronic hepatitis C (CHC) it is not exceptionally medical problem but a significant social and economic threat, taking into ac-
count the unfavorable consequences of this disease: cirrhosis and hepatocellular carcinoma. And as a result – the high level of disability. 
In the article are presented the results of examination of 41 patients with chronic hepatitis C, with 1 genotype, who received the antiviral 
therapy (AVT). All patients underwent determination of the level of 5-hydroxycholeсalсeferol (25-OH vit D3), vitamin D and also the 
study of IL-28B polymorphism as the one of predicators of response to AVT. It was demonstrated, that in patients with hepatitis was 
observed the deficit of 25-OH vit D3 and general vitamin D. It was established, that in patients with the normal 25-OH vit D3 level SVR 
(stable viral response) was observed in 1,4 times more often than in patients with deficit of 25-OH vit D3. That is the level of 25-OH vit D3 
can be considered as a predicator of SVR to AVT. 
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1. Introduction
Chronic hepatitis C is considered by WHO as the serious problem of health protection that 
is caused by the global widening, long clinical course, unfavorable consequences. According to the 
WHO data, near 130–150 mln. of population suffer from CHC for today, but it is considered that 
the real number is significantly larger [1]. By the level of infection Ukraine occupies one of the first 
places in Europe and there is observed the permanent growth of the CHC morbidity index [2–5]. 
HCV-infection is characterized with the high rate of chronization with the further risk of formation 
of cirrhosis and hepatocellular carcinoma and also with systemacy of injuries with development of 
extra-liver manifestations [6].
According to the modern data, the level and character of infectious process depend on both 
features of viral antigens and cooperation of all protective mechanisms of macroorganism. 
The use of standard AVT gives a possibility to attain the stable viral response (SVR) in pa-
tients with CHC, infected with 1 HCV genotype in 42–46 % of cases, infected with 2/3 HCV gen-
otype – in 76–82 % [7]. Introduction of preparations with the direct antiviral action into clinical 
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practice gave a possibility to raise the effectiveness of AVT in patients with CHC essentially [8, 9]. 
But the high value of this therapy limits its wide use. 
The node question in the treatment of patients with CHC is the stop of progress of hepatic fibrosis 
that is the consequence of the different mechanisms of injury of tissue, caused by the viral infection with 
the final development of cirrhosis and its complications [10]. In this complex of interactions between 
the hepatic and metabolic factors the share of researches that prove the role of vitamin D as the one of 
predicators of development and progress of fibrosis among patients with chronic hepatitis C grows.  
The numerous researches in many directions proves the one of the main roles of vitamin D 
in the development of pathological processes among patients with CHC, tumor and cardiometabolic 
disorders and motivated to the further genetic, clinic and experimental researches for the study of 
metabolism and role of vitamin D [11–13]. Thus, several researches established that the level of vita-
min D in the blood serum can be used as an additional prognostic marker of the stable viral response 
at standard therapy of viral hepatitis C. Thus, some scientists proved that the low level of 25-OH 
vitamin D3 (25-hydroxyvitamin D3) was associated with the low level of response to antiviral therapy 
in such patients [13–15]. In several researches were not revealed interconnections between these indices. 
2. Aim of research
The study of changes of indices of 5-hydroxycholecalceferol (25-OH vit D3) and general 
vitamin D in patients with CHC and assessment of their influence on AVT. 
3. Materials and methods of research
41 patients with CHC were under observation. Among the examined were 25 (61 %) men, 
16 (39 %) women, the mean age of patients was 44,02±1,66 years. All patients were on stationary 
or outpatient treatment in Vinnitsa city hepatologic center during 2015–2016. 
1 genotype was determined in all patients. Most patients had the low viral load (74,42 % – less 
than 800 000 Ul/ml). All patients underwent combined AVT. Interleukin 28 B was determined in all 
patients before the start of AVT. Antiviral therapy was realized by the scheme pegylated interferon in 
combination with ribavirin during 48 weeks in standard dosing. The main aim of CHC treatment was 
an attainment of SVR that is the absence of RNA VCH at examination by PMR in 24 weeks after the 
end of complete course of AVT. 
The control group included 30 practically healthy persons, 16 men (53,3 %) and 14 women 
(46,7 %), mean age was 35,8±1,9 years.  
Statistical processing of the received results was carried out using “STATISTICA 5,5” with the 
help of parametric and nonparametric methods of assessment of the received results. The last one belongs 
to CRI of Vinnitsa national medical institution of M. I. Pirogov, license № АХХR910A374605FA). 
Experimental procedures.
Diagnosis CHC was proved by detection of anti-HCV-RNA and HCV-RNA in patients’ 
blood serum on analyzers and test-systems: Cobas 6000, Roche Diagnostics (Swiss), Vitrotest 
(CIS), amplifiers Rotor-Gene («Corbett Research», Australia), ТС-AmpliSense (Russia). All exam-
ined were infected with virus of 1 genotype. 
The levels of 25-hydroxycholecalceferol (25-OH vit D3), general vitamin D, general and 
ionized calcium and phosphorus were determined in all patients. The level of 25-hydroxychole-
calceferol (25-OH vit D3) was determined by the method of chemiluminescence magnetic immune 
analysis on test-systems ABBOT Diagnostics (USA). The general vitamin D was determined by 
the method of immune-enzyme analysis using test-systems EUROIMMUN (Germany). The levels 
of general and ionized calcium and phosphorus were determined on test-systems Roche Diagnos-
tics (Suiss). The complex of examination of patients also included the determination of ALT, AST, 
general bilirubin levels. 
4. Results of research
Among patients with CHC men prevailed in 1,6 times (61 %) over women (39 %). Most pa-
tients (43,9 %) were in age diapason of 40–49 years. The least number of patients was younger than 
19 years, that was 2,4 % (Fig. 1).
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Fig. 1. Distribution of patients with CHC by age (n=41)
Before the start of AVT among patients with CHC prevailed persons with the low level of 
viral load that were 73,2 % (Fig. 2).
Fig. 2. Distribution of patients with CHC by the level of viral load 
Analyzing the indices of cytolytic syndrome, it was established, that activity of ALT and 
AST exceeded the referent norms in 1,6 and 1,7 times respectively.
The mean indices of ALT were 1,08±0,13 mmol/hour/l and AST – 0,71±0,07 mmol/hour/l. 
At comparison of indices of 25-OH vit D3, general vitamin D, general and ionized calcium 
and phosphorus in patients with CHC with the ones of healthy persons the reliable difference was 
detected only between indices of 25-OH vit D3 and general vitamin D. Thus, the level of vitamin 
D was in 1,3 times higher in healthy persons comparing with patients with CHC and the level of 
25-OH vit D3 in 1,9 times respectively (Table 1).
At analysis of indices of 25-OH vit D3 in patients with CHC it was established, that in over-
whelming majority of patients was deficit of 25-ОH vit D3, that was 85,4 % of persons. Whereas the 
normal level of 25-ОН vit D3 was observed only in 6 patients that was 14,6 % (Fig. 3).
As to polymorphism of interleukin 28В as the one of predicators of SVR in patients with 
CHC, it was established, that CT genotype was determined in overwhelming majority of patients 
that was 65,9 % (27 persons), СС – in 19,5 % (8 persons). The least number of patients had ТТ 
genotype that was 14,6 % (6 persons).
We analyzed the response on AVT depending on 25-ОН vit D3 level. It was revealed, that in 
patients with the normal 25-ОН vit D3 level SVR was observed almost in 68,3 % of patients against 
31,7 % of ones with deficit of 25-ОН vit D3 (Fig. 4).
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Table 1
Distribution of patients with CHC depending on indices of 25-OH vit D3, general vitamin D and ionized 
calcium, phosphorus 
Indices Patients with CHC (n=41) Healthy (n=30)
General vitamin D, ng/ml 27,99±1,45* 37,54±1,45
25-OH vit D3, ng/ml 20,29±1,38* 38,54±1,02
General calcium (serum), mmol/l 2,43±0,07 2,32±0,02
Ionized calcium (serum), mmol/l 1,25±0,01 1,28±0,04
Phosphorus, mmol/l 1,09±0,04 1,15±0,01
Note: p<0,05 – reliable difference between groups 
Fig. 3. Distribution of patients with CHC depending on 25-OH vit D3 level
Fig. 4. Distribution of patients with CHC depending on 25-ОН vit D3 level and response to AVT
5. Discussion of the results of research
The researchers pay more and more attention to the IL-28B, which gene polymorphism is a 
reliable prognostic criterion of the effectiveness of treatment of hepatitis С [16]. There was estab-
lished the prevalence of different polymorphisms of gene of this cytokine among Ukrainians. Thus, 
SNP СС rs12979860 was revealed in 56 %, СТ – in 34 %, ТТ – in 10 % of examined, whereas the 
frequency of revelation of СС rs12979860 allele among patients with chronic HC is significantly 
lower that is 36,8 % [17], that is possibly connected with the more frequency of spontaneous НСV 
clearance after the acute form of infection. 
In our research at the study of polymorphism of interleukin 28В among patients with CHC 
was established that CT genotype is most frequent – in 65,9 % of persons.
It was revealed that 25-ОН vit D3 level was in 1,9 times lower in patients with CHC than the 
one in healthy persons, whereas the level of general vitamin D only in 1,3 times. 
There are the contradictory data about connection of vitamin D with the progress of CHC. 
According to the data of several authors, the deficit of vitamin D can influence the effectiveness 
of AVT and the progress of disease [18]. According to the data of other authors, there were not 
revealed any differences in the level of vitamin D depending on stage of fibrosis and sensitivity to 
AVT in patients with CHC [19].
In the other research was revealed that the frequency of SVR among patients of Caucasian race 
correlated with 25-ОН vit D3 level, whereas the frequency of SVR was higher in patients with normal 
or heightened 25-ОН vit D3 level (SVR was observed in 46 % of patients at the normal concentration of 
25-ОН vit D3 in blood serum; р=0,008) [20].
We revealed that in patients with the normal 25-ОН vit D3 level SVR was observed in 1,4 times 
more often than in patients with deficiency of 25-ОН vit D3.
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6. Conclusions
1. In patients with CHC comparing with practically healthy persons the deficit of 25-ОН vit D3 
and general vitamin D was detected reliably more often in 1,9 and 1,3 times respectively.  
2. It was detected, that after the end of AVT in patients with CHC SVR was observed reliably 
(p<0,05) more often (68,3 %) in persons who have the normal 25-ОН vit D3 level.
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